All nucleated cells in higher vertebrates express MHC class I proteins on their surface (HLA class I in humans), while only a subset of cells (mostly professional antigen-presenting cells) express MHC class II.
Malignant cells, which display tumor-associated peptides on MHC molecules, can be recognized and killed by T cells. There is a growing evidence that the tumor rejection process can be boosted by suitable immunostimulatory approaches, such as treatment with anti-PD-1 antibodies or immunocytokines.

Philochem scientists have developed powerful methodologies for the detailed analysis of human and mouse MHC-bound peptides. Indeed, thousands of MHC class I and MHC class II bound peptides can be identified with high confidence, using a combination of immunocapture and state-of-the-art mass spectrometry. Once the tumor- or disease-associated peptides have been identified, they can be incorporated in artificial MHC tetramers to test their immunoreactivity. Insights into T cell recognition processes are invaluable for the development of immunomodulatory strategies against cancer and chronic inflammatory conditions. Furthermore, MHC peptidome analysis provides useful biomarkers for patient stratification strategies.


Probst et al. (2019) Clin Cancer Res, 25, 698-709
Probst et al. (2017) Cancer Res, 77, 3644-54
Ritz et al. (2017) Proteomics, 17, 10.1002/pmic.201600364
Gloger et al. (2016) Cancer Immunol Immunother, 65, 1377-93
Ritz et al. (2016) Proteomics, 16, 1570-80
Sofron et al. (2016) Eur J Immunol, 46, 319-28


By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy